Table 2

Clinical, Immunological, and Virologic Details of the 5 Pediatric and 17 Adult Subjects Studied by Tetramer and Intracellular IFN-γ Staining Assay as Shown in Fig. 2 D and 3

GroupSubjectCTL specificityTetramer staining (/CD8+)ICS (/CD8+)Ratio ICS/tetramerTime HIV infectedViral loadARTDuration of ART regimenCD4+ T cellsp24 Gag-specific T helper response (IFN-γ ICS/ CD4+)
%%%yrRNA copies/ ml plasmayrcells/mm3%%
GroupADBN-11B42 Gag3.313.451044867,724Naive277150.00
DBN-12B42 Gag0.590.2441 >4NANaive433130.03
9354A2 Gag1.881.4477 >13147,000Naive18080.00
115iA2 Gag0.330.1958 >1335,000Naive398180.00
63gA2 Gag0.850.66781020,800Naive37517ND
2211A2 Gag0.310.2787 >15175,000Naive723290.00
Group BDBN-1B42 Gag3.121.936311,364Naive1,027560.18
021-BMCB42 Gag3.521.83521411,849Dual365016ND
026-BMCB42 Gag1.791.287291,261Dual3681360.12
032-BMCB42 Gag2.331.898181,436Triple3538240.00
SPB8 Gag0.100.0440NK26,037Naive516300.04
SPB8 Nef1.791.2670
FWWB8 Gag1.491.4094 >419,627Naive506240.01
FWWB8 Nef0.240.2396
MCWB8 Gag0.170.19112 <1>750,000Naive48828ND
MCWB8 Nef1.150.8877
GVB8 Nef0.430.2763 <1111,000Nil0.197032ND
AAA2 Gag0.730.6792 >3<50Triple0.326723ND
161jA2 Gag1.430.574021<50Naive670415.80
661A2 Gag0.760.6383NK4,100Naive1,34447ND
199pgA2 Gag0.490.3163 >113,700Naive811270.13
JFMA2 Gag0.170.13762307Nil0.3555380.07
BNN-06A2 Gag0.220.1673112,000Naive11NANA0.03
GroupC019-BMCA2 CMV0.670.4872726,366Dual31,148240.40
009-BMCA2 CMV1.221.22100103,329Quad1161150.02
AAA2 CMV1.070.9084>3 <400Triple0.326738ND
SIA2 CMV0.170.1376HIV
PGB7 EBV0.260.1869HIV
A2 EBV3.012.9297
  • Antiretroviral therapy designated as follows: Naive; Nil (previously on therapy but taking no therapy when studied); Mono, monotherapy; Dual, two drugs; Triple, three drugs; Quad, four drugs. ICS, intracellular IFN-γ staining; ART, antiretroviral therapy; NA, coincident data unavailable; NK, duration of infection not known.